Dr. Julie Brahmer (@juliebrahmer) 's Twitter Profile
Dr. Julie Brahmer

@juliebrahmer

Director of @HopkinsThoracic, Director of the Upper Aerodigestive Disease Program, @bloombergkimmel, Professor of Oncology @HopkinsMedicine and @hopkinskimmel

ID: 1358983980935168001

linkhttps://www.hopkinsmedicine.org/kimmel_cancer_center/cancers_we_treat/lung_cancer_program/ calendar_today09-02-2021 03:41:35

217 Tweet

1,1K Takipçi

117 Takip Edilen

Dr. Julie Brahmer (@juliebrahmer) 's Twitter Profile Photo

Thanks so much to my amazing co-chairs of the ⁦Ana I. Velázquez Mañana, MD, MSc, FASCO⁩ & Katie Lai! Thx for making #LEAD2024 awesome! Thx to our many great faculty & our attendees! Can’t wait till next year❤️

Thanks so much to my amazing co-chairs of the ⁦<a href="/AnaVManana/">Ana I. Velázquez Mañana, MD, MSc, FASCO</a>⁩ &amp; Katie Lai!  Thx for making #LEAD2024 awesome!  Thx to our many great faculty &amp; our attendees!  Can’t wait till next year❤️
Jordi Remon (@jordiremon) 's Twitter Profile Photo

In early-stage NSCLC 🫁 IO is a reality with several approvals by FDA/EMA 👏🏻. ADJ trials with IO « more controversial » , Hwv, neoadj and periop CT+O trials more consistent results. Are we sure periop IO is better than only induction CT+IO in OS? Overtreating 🫁 w/pCR? #ILCS24

In early-stage NSCLC 🫁 IO is a reality with several approvals by FDA/EMA 👏🏻. ADJ trials with IO « more controversial » , Hwv, neoadj and periop CT+O trials more consistent results. Are we sure periop IO is better than only induction CT+IO in OS? Overtreating 🫁 w/pCR? #ILCS24
Dr. Julie Brahmer (@juliebrahmer) 's Twitter Profile Photo

What a way to kick off#winterlung in sunny Fl! Our esteemed colleagues Dr Patricia Rivera and Dr Lecia Sequist ⁦Lecia Sequist, MD, MPH⁩ talking about Lung Cancer Screening. Thank you!!!

What a way to kick off#winterlung in sunny Fl! Our esteemed colleagues Dr Patricia Rivera and Dr Lecia Sequist ⁦<a href="/LeciaSequist/">Lecia Sequist, MD, MPH</a>⁩ talking about Lung Cancer Screening.   Thank you!!!
Dr. Estela Rodriguez (@latinamd) 's Twitter Profile Photo

#WLC25 Excellent case presented by Coral Olazagasti, MD Sylvester Comprehensive Cancer Center discussing ALK+ #lungcancer primary resistance to ALK TKIs and what to do when our usual therapies stop working. Key points : -repeat biopsies and NGS is 🔑 -refer to clinical trials early -discuss palliative care

#WLC25 Excellent case presented by <a href="/COlazagasti/">Coral Olazagasti, MD</a> <a href="/SylvesterCancer/">Sylvester Comprehensive Cancer Center</a> discussing ALK+ #lungcancer primary resistance to ALK TKIs and what to do when our usual therapies stop working. 
Key points :
-repeat biopsies and NGS is 🔑
-refer to clinical trials early
-discuss palliative care
Dr. Estela Rodriguez (@latinamd) 's Twitter Profile Photo

#WLC25 Susan Combs Scott, MD Johns Hopkins Thoracic Oncology knocked it out of the park⚾️🏟️winning 🥇argument that osimertinib monotherapy is no longer the 2025 standard for 1L EGFR+ NSCLC (highlighting FLAURA2 & MARIPOSA trials) EGFR Resisters #lcsm PER

#WLC25 <a href="/SusanScottMD/">Susan Combs Scott, MD</a> <a href="/HopkinsThoracic/">Johns Hopkins Thoracic Oncology</a> knocked it out of the park⚾️🏟️winning 🥇argument that osimertinib monotherapy is no longer the 2025 standard for 1L EGFR+ NSCLC (highlighting FLAURA2 &amp; MARIPOSA trials) <a href="/EGFRResisters/">EGFR Resisters</a> #lcsm <a href="/gotoPER/">PER</a>
ECOG-ACRIN Cancer Research Group (@eaonc) 's Twitter Profile Photo

Do you have advanced non-small cell #LungCancer and are aged 70 or older? If so, you may be able to participate in this study of a new treatment approach. Learn more: bit.ly/ea5221-achieve cc: Efrat Dotan MD Carolyn Presley, MD MHS Balazs Halmos

Do you have advanced non-small cell #LungCancer and are aged 70 or older? If so, you may be able to participate in this study of a new treatment approach. Learn more: bit.ly/ea5221-achieve cc: <a href="/efratdotan/">Efrat Dotan MD</a> <a href="/CPresGeriOncMD/">Carolyn Presley, MD MHS</a> <a href="/BalazsHalmosMD/">Balazs Halmos</a>
TLC Conference (@tlcconference) 's Twitter Profile Photo

The 3rd annual, IASLC endorsed #TexasLung25 is right around the corner! With 80+ leading national experts and community oncologists, this 2-day CE-accredited conference will equip HCPs with actionable insights for advancing #lungcancer care. Register now: hubs.ly/Q0393vxk0

The 3rd annual, <a href="/IASLC/">IASLC</a> endorsed #TexasLung25 is right around the corner! With 80+ leading national experts and community oncologists, this 2-day CE-accredited conference will equip HCPs with actionable insights for advancing #lungcancer care. Register now: hubs.ly/Q0393vxk0
Dr. Estela Rodriguez (@latinamd) 's Twitter Profile Photo

#TexasLung25 Women in Thoracic Oncology breakfast with great leaders discussing their career paths to leadership: ➡️Choosing your focus ➡️Overcoming Challenges ➡️Pivoting & embracing opportunity Dr. Julie Brahmer Karen Kelly Narjust Florez, MD, FASCO Loretta Erhunmwunsee, MD, FACS Mara Antonoff, MD, FACS #lcsm

#TexasLung25 Women in Thoracic Oncology breakfast with great leaders discussing their career paths to leadership:

➡️Choosing your focus
➡️Overcoming Challenges
➡️Pivoting &amp; embracing opportunity

<a href="/JulieBrahmer/">Dr. Julie Brahmer</a> <a href="/karenkellymd/">Karen Kelly</a> <a href="/NarjustFlorezMD/">Narjust Florez, MD, FASCO</a> <a href="/LorettaEMD/">Loretta Erhunmwunsee, MD, FACS</a> <a href="/maraantonoff/">Mara Antonoff, MD, FACS</a> #lcsm
Dr. Antonio Calles 🫁🚭 (@tony_calles) 's Twitter Profile Photo

💥 Tarlatamab improves survival in 2nd line SCLC. DeLLphi-304 results demonstrated statistical significant and clinically meaningful improvement in overall survival compared to standard of care chemotherapy. #LCSM ⁦SmallCellSMASHERS⁩ investors.amgen.com/news-releases/…